Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Fibrocell Science, Inc. (FCSC) Reports Promising Results from Study on Generation of iPS Cells

Fibrocell Science is an autologous cell therapy company focused on the development of innovative products for medical, aesthetic, and scientific applications. The company is trying to advance the scientific, medical, and commercial potential of autologous skin and tissue as well as its innovative cellular processing and manufacturing technology.

The company is working in a research collaboration with the University of California, Los Angeles, on the conversion of dermal fibroblasts into pure functional human cell types that may have greater regenerative capacity. This research will set the stage for future diagnostics and treatments based on each individual’s cells for diseases such as Parkinson’s, diabetes, and heart disease.

Fibrocell announced today promising results from a study demonstrating a potential mechanism for converting research-grade adult skin cells into clinical-grade induced pluripotent (iPS) stem cells. The study was conducted under the lead of James Bryne, Ph.D. assistant professor at the UCLA Department of Molecular and Medical Pharmacology, at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.

The study provided proof of concept for this reprogramming method of converting adult skin cells to iPS cells. But it also confirmed that scientists can remove unwanted non-human contaminants from stem cell populations. The iPS cells produced during the study had the ability to transform into other critical cell types such as those of the brain, liver, and heart.

Using skin cells is usually easier on the patients since a skin biopsy is minimally invasive, less painful, and less time-consuming than obtaining cells from bone marrow or fat tissue. This programming approach developed by Fibrocell and UCLA may be used by researchers to evaluate new drug compounds for safety and to develop patient-specific therapies for a number of diseases.

For additional information about Fibrocell Science and this latest research study, please visit www.fibrocellscience.com

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Comments are closed.